Novation said today that it inked an exclusive deal with Edwards Lifesciences (NYSE:EW), marking Novation’s 1st entry into the replacement heart valve market.
The 3-year, sole-source contract makes Edwards’ line of heart valves available to Novation’s 100,000-strong membership, according to a press release.
The companies already had a deal going for critical care products, according to the release.
"This heart valve agreement enables Novation to provide marked additional value to hospitals and their patients with Edwards Lifesciences’ clinically proven, life-saving heart valve devices," Novation sourcing operations vice president David Richman said in prepared remarks. "We are proud that Edwards believes in Novation’s unique capabilities and we look forward to working with them to deliver value to the members we serve."
"Edwards invests significantly in the development of new treatment options that can provide meaningful benefits to patients, and we look forward to working in partnership with Novation so that heart valve patients can get the treatments they need from Edwards’ comprehensive valve portfolio," added Edwards heart valve vice president Donald Bobo Jr.